Article Sidebar
Main Article Content
Abstract
COVID-19 outbreak is currently being concerned for managing patients with
immunological disorders nowadays, including SLE. Lupus is a complex
autoimmune disease characterized by the presence of autoantibodies that against
cell nucleus involved many organs in the body. Patients with SLE will increase
risk of severe infection because the intrinsic respond attack with their immune
respond though immunosuppressive drugs consumption, and will potentially
damage some organs target associated with their disease. Lupus have multiple
clinical manifestations with a fluctuating symptom. Patient who come with the
symptom ofbreathlessness will getworse day by day. The symptom could be felt in
the same time as fatigue, joint pain, hair loss, malar rash, oral ulcer, pleural
effusion and swollen feet. There's a patient with antinuclear antibody positive for
anti-smith and anti-Ro/SS-A. She was diagnosed with COVID-19, SLE with
nephritis, haemolytic anemia, vasculitis and pleural effusions. The clinical
manifestations of this patient indicate a COVID-19 with lupus nephritis that has
severe disease. She was being treated with methylprednisolone and
hydroxychloroquine for SLE and azithromycin plus oseltamivir as a therapy for
COVID-19. The effect of hydroxychloroquine on SARS-CoV-2 was better seen in
patients with SLE who gotthe medication regularly. Patients went home after 24
days of hospitalization after negative RT-PCR results and clinical improvement of
LES.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
